Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Add as a preferred source on Google
ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2018 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the Company is scheduled to present new data on its allogeneic CRISPR-based CAR-T programs at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 16, 2018 in Chicago, IL.
Presentation: Allogeneic chimeric antigen receptor T cells targeting B cell maturation antigen
Session: Adoptive Cell Therapy 1
Time and Date: 8:00 AM – 12:00 PM CDT, Monday, April 16, 2018
Location: McCormick Place South (Level 3), Exhibit Hall A, Section 24, Poster 1540
Presentation: Allogeneic CRISPR engineered anti CD70 CAR T cells demonstrate potent preclinical activity against both solid and hematological cancer cells
Session: Adoptive Cell Therapy 2
Time and Date: 1:00 PM - 5:00 PM CDT, Monday, April 16, 2018
Location: McCormick Place South (Level 3), Exhibit Hall A, Section 24, Poster 2551
Following presentation at the meeting, the posters will be available on CRISPR Therapeutics’ website at http://www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.
CONTACTS
CRISPR Therapeutics
Investors:
Chris Erdman
617-307-7227
[email protected]
or
Chris Brinzey
Westwicke Partners
339-970-2843
[email protected]
Media:
Jennifer Paganelli
WCG for CRISPR
347-658-8290
[email protected]
